Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;3(3):e119-27.
doi: 10.1016/S2352-3026(15)00289-6. Epub 2016 Feb 20.

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

Margaret L Green  1 , Wendy Leisenring  2 , Hu Xie  3 , T Christopher Mast  4 , Yadong Cui  4 , Brenda M Sandmaier  5 , Mohamed L Sorror  5 , Sonia Goyal  6 , Sezen Özkök  6 , Jessica Yi  6 , Farah Sahoo  6 , Louise E Kimball  6 , Keith R Jerome  7 , Morgan A Marks  4 , Michael Boeckh  8
Affiliations

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

Margaret L Green et al. Lancet Haematol. 2016 Mar.

Abstract

Background: Although cytomegalovirus viral load is commonly used to guide pre-emptive therapy in the post-transplantation setting, few data are available correlating viraemia with clinical endpoints. We therefore investigated the association between cytomegalovirus viral load and mortality in the first year after haemopoietic stem cell transplantation.

Methods: In this retrospective cohort study, we included patients from the Fred Hutchinson Cancer Research Center, WA, USA, who received an allogeneic haemopoietic stem cell transplantation between Jan 1, 2007, and Feb 28, 2013, were cytomegalovirus seropositive or had a seropositive donor, and underwent weekly plasma cytomegalovirus monitoring by PCR through to day 100 post-transplantation. Cox proportional hazards models were used to estimate the association of cytomegalovirus viral load at different thresholds with overall mortality by 1 year post-transplantation, adjusting for the use of pre-emptive therapy and other factors such as neutropenia, and graft-versus-host disease.

Findings: Of the 1037 patients initially selected for inclusion in this cohort, 87 (8%) patients were excluded because of missing cytomegalovirus testing and 24 (2%) were excluded because of their participation in cytomegalovirus prophylaxis trials. In the remaining 926 patients included in this study, the cumulative overall mortality was 30·0% (95% CI 26·9-33·0) 1 year after haemopoietic stem cell transplantation. 95 patients developed cytomegalovirus disease; death was directly attributable to cytomegalovirus disease in three (1%) of 263 patients who died in the first year after transplantation. A cytomegalovirus viral load of 250 IU/mL or greater was associated with increased risk of early (day 0-60 post-transplantation) death (adjusted hazard ratio [HR] 19·8, 95% CI 9·6-41·1). The risk was attenuated after day 60 (adjusted HR 1·8, 95% CI 1·3-2·3). Similar associations were noted for higher cytomegalovirus viral load thresholds.

Interpretation: Cytomegalovirus viraemia is associated with an increased risk of overall mortality in the first year after haemopoietic stem cell transplantation, independent of the use of pre-emptive therapy, and with evidence of a positive dose-response relationship. These data indicate the suitability of viral load as a surrogate clinical endpoint for clinical trials for cytomegalovirus vaccines, biologics, and drugs.

Funding: Merck and Co, National Institutes of Health.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Dr. Green reports grants from Merck & Co., Inc. during the conduct of the study; grants and personal fees from Astellas outside the submitted work. Dr. Leisenring and Ms. Xie received grants from Merck & Co., Inc. for the conduct of the study. Drs. Mast, Cui, and Marks are current employees of, and own stock in Merck and Co. Inc. Dr. Sorror reports personal fees from Jazz Pharmaceuticals, outside the submitted work. Dr. Boeckh reports grants and personal fees from Merck & Co., Inc., during the conduct of the study; grants and personal fees from Astellas, Shire, Roche/Genentech, Gilead and Chimerix; personal fees from Clinigen and Microbiotix, outside the submitted work. Drs. Sandmaier, Goyal, Özkök, Sahoo, Kimball, Jerome, and Ms. Yi have nothing to disclose.

Figures

Figure 1
Figure 1. Cumulative incidence of: (a) CMV reactivation at different levels of viremia (any positive, >150 IU/ml, >500 IU/ml, and >1000 IU/ml); (b) Initiation of preemptive therapy*; and (c) CMV disease by 1 year after HCT for all subjects
*Preemptive antiviral therapy was initiated with either induction-dose ganciclovir (5 mg/kg intravenously every 12 hours), foscarnet (90 mg/kg intravenously every 12 hours), or valganciclovir (900 mg orally every 12 hours). Induction therapy was continued for at least one week followed by at least two weeks of maintenance (once daily) therapy until cessation of CMV viremia.
Figure 2
Figure 2. Adjusted HR and 95% CI from multivariable Cox proportional hazards models evaluating CMV viral load as a time-dependent risk factor for CMV disease by 1 year after HCT, stratified by use of preemptive therapy (n= 926)
Models each adjusted for CMV serostatus, HLA matching, cell source, underlying disease, HCT-CI, and disease risk.
Figure 3
Figure 3. Adjusted HR and 95% CI from multivariable Cox proportional hazards models evaluating CMV viral load as a time-dependent risk factor for overall mortality with (a) viral load as a categorical variable and (b) viral load as a threshold; and non-relapse mortality with (c) viral load as a categorical variable and (d) viral load as a threshold by 1 year after HCT (n=926)
Comparator group for categorical models (a and c) is patients with no CMV reactivation. Adjustment factors for overall mortality models: patient age,transplant year, underlying disease, disease risk, HCT-CI score, acute GVHD grade, neutropenia, and preemptive therapy. Adjustment factors for non-relapse mortality models: patient, HLA-matching, disease risk, HCT-CI score, acute GVHD, chronic GVHD, neutropenia, and preemptive therapy. Results of the categorical model for all factors are available in the appendix (page 2)
Figure 4
Figure 4. Cumulative incidence of (a) overall mortality and (b) non-relapse mortality by 1 year after HCT among day-100 survivors (n= 832) stratified by maximum CMV viral load before day 100 and (c) results from multivariable Cox proportional hazards models evaluating maximum CMV viral load before day 100 as a risk factor for overall and non-relapse mortality
Covariates for overall mortality models include: age, donor relation, transplant year, underlying disease, disease risk, HCT-CI score, neutropenia before day 100, CMV viremia after day 100 (time-dependent). Covariates for non-relapse mortality models include: age, donor relation, transplant year, disease risk, HCT-CI score, acute GVHD, chronic GVHD, neutropenia before day 100, CMV viremia after day 100 (time-dependent).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. The Lancet Infectious Diseases. 2011;11:284–92. - PubMed
    1. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation. New England Journal of Medicine. 2013;369:1227–36. - PubMed
    1. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation. New England Journal of Medicine. 2014;370:1781–9. - PubMed
    1. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91:78–83. - PubMed
    1. Gerna G, Lilleri D, Caldera D, Furione M, Zenone Bragotti L, Alessandrino EP. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008;41:873–9. - PubMed

Publication types